Merck news

• 

  23 September 2025

  Merck and Siemens Partner to Boost AI in Drug Development

  The partnership aims to enhance drug discovery with digital solutions, integrating AI and data to streamline processes and accelerate scientific progress.
• 

  19 September 2025

  FDA Approves Merck's Subcutaneous KEYTRUDA QLEX for Solid Tumors

  KEYTRUDA QLEX, a subcutaneous immune checkpoint inhibitor, offers comparable efficacy to IV KEYTRUDA in treating metastatic NSCLC, with administration possible in one minute by healthcare providers.
• 

  19 September 2025

  Merck's ENFLONSIA™ Recommended by EU CHMP for RSV Prevention in Infants

  ENFLONSIA™ awaits EU approval for infant RSV prevention, offering a single-dose option for all weights. Backed by Phase 2b/3 and Phase 3 trials, decision expected by year-end.
• 

  19 September 2025

  Merck Gains EU CHMP Support for KEYTRUDA SC and New Head and Neck Cancer Use

  CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.
• 

  11 September 2025

  Merck's CAPVAXIVE Shows Positive Immune Response in At-Risk Youth

  CAPVAXIVE outperforms PPSV23 in immune response for at-risk children, with comparable safety, covering more serotypes. Results to be shared with global regulators.
• 

  7 September 2025

  Ifinatamab Deruxtecan Shows 48.2% Response in ES-SCLC Phase 2 Trial by Daiichi Sankyo and Merck

  Ifinatamab deruxtecan achieved a 48.2% response rate in ES-SCLC patients, with ongoing regulatory discussions and consistent safety profile.

• 

  2 September 2025

  Merck's Oral PCSK9 Inhibitor Enlicitide Achieves Key Endpoints in Hypercholesterolemia Study

  Enlicitide shows significant LDL-C reduction and favorable safety in Phase 3 trials, meeting all primary and key secondary endpoints for hypercholesterolemia treatment.
• 

  30 August 2025

  Bayer Presents VICTOR Phase III Trial Results for Vericiguat at ESC Congress 2025

  Vericiguat didn't reduce primary endpoint risk in HFrEF patients but showed fewer cardiovascular deaths. Safety profile consistent with previous trials.
• 

  6 January 2025

  MSD Ireland to Acquire WuXi Vaccines' Dundalk Facility

  The acquisition involves a €500M investment, adding 1,000 jobs across Ireland by 2025, enhancing vaccine production capabilities and strengthening Ireland's pharma sector.
• 

  11 June 2024

  Merck Invests €62M in New Quality Control Facility

  The new 10,000 sqm facility in Darmstadt will house 135 employees, meet sustainability standards, and enhance quality control for life science products, supporting Merck's €1.5B investment program.
• 

  25 April 2024

  Merck Invests €300 Million in New Research Center in Darmstadt

  The new center will focus on antibody and mRNA research, supporting 550 employees by 2027. It aims for near carbon-neutral operations and gold certification from the German Sustainable Building Council.
• 

  8 September 2022

  Merck Invests €130 Million to Expand Manufacturing in Molsheim, France

  The investment will boost single-use assembly production, create 800 jobs by 2028, and support growth in novel therapies and vaccines, aligning with sustainability goals and global expansion plans.
• 

  23 August 2022

  MSD Ireland Expands Carlow Site

  Over 100 new jobs will be created as a new facility for next-gen oncology biologics begins construction, operational by 2025, adding to the existing 530 staff and 700 construction roles.
• 

  23 May 2022

  Merck Invests €440 Million to Expand Manufacturing in Cork, Ireland

  The investment will boost membrane and filtration manufacturing, create 370 jobs by 2027, and support novel therapies, vaccines, and diagnostics, aligning with sustainability goals.
• 

  28 March 2019

  Merck Expands Biotech Manufacturing Capacity

  €150M investment in Aubonne, Switzerland, for new building with advanced tech to boost production of biotech medicines, meeting global demand. Completion expected by 2023.
• 

  11 August 2014

  Merck Millipore Invests €12 Million to Expand French Facility

  The investment will enhance RTU Media production, ensure supply security, and centralize R&D in Molsheim, supporting global demand and market growth.
• 

  20 May 2014

  Merck to Invest €50M in Bari Production Site

  The investment will expand production for rising biopharmaceutical demand, focusing on sterile filling and packaging. The Bari site benefits from skilled employees and good infrastructure.